# US 2019/0375714 A1 · Quinoline compound, preparation method and medical use therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0375714 A1
- Document ID: US20190375714A1
- Status: Published application
- Kind: A1
- Application number: 16/480,292
- Filed: 2018-02-06
- Published: 2019-12-12
- Earliest claimed: 2017-02-07
- Assignees: Ancureall Pharmaceutical (Shanghai) Co., Ltd.
- Applicants: Ancureall Pharmaceutical (Shanghai) Co., Ltd.
- Inventors: Jutong Si; Meifeng Jiang; Jiayan Li; Han Zeng; Huabin Yang
- Web page: https://patentgrep.com/patent/US20190375714A1

## CPC

- C07D 215/16: with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A61K 31/47: Quinolines; Isoquinolines
- A61K 31/4709: Non-condensed quinolines and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07D 215/02: having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a quinoline compound, as well as a preparation method and medical use therefor. Specifically, the present invention relates to a novel quinolone compound represented by the general formula (I) and a method for preparing the same, as well as a use therefor as an inhibitor for a plurality of protein kinases, and a use in the prevention and/or treatment of cancer in particular; the definition of each group in the general formula (I) is the same as the definition in the description.

## Claims

### Claim 1

A compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof,
wherein:
A is selected from the group consisting of NR4, S and O;
W1 and W2 are each independently selected from the group consisting of N and CR3;
R1 is selected from the group consisting of H and OR10;
R10 is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, —RuORx, —RuN(Ry)(Rz), —RuS(O)nN(Ry)(Rz) and —RuS(O)nRx; wherein the alkyl, alkenyl, alkynyl and cycloalkyl are each independently and optionally further substituted with one or more groups selected from the group consisting of halogen, cyano, hydroxyl, amino and alkyl;
R2 is selected from the group consisting of Q groups and the following structures:
R0 is identical or different and each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl and alkynyl, wherein the alkyl is optionally substituted with one or more alkoxy groups;
R3 and R8 are each independently selected from the group consisting of halogens, —N(Ry)(Rz) and Q groups;
R4 is selected from the group consisting of hydrogen, alkyl, alkoxy and cycloalkyl;
R6 is selected from the group consisting of hydrogen, halogen, alkyl, haloalkyl, alkoxy, —ORuORx, —ORuN(Ry)(Rz) and —N(Ry)(Rz);
R7 is selected from the group consisting of hydrogen, halogen, alkyl and cyano;
R9 is selected from the group consisting of hydrogen, halogen, alkyl and haloalkyl;
R5 is selected from the group consisting of hydrogen, alkyl, alkoxy and cycloalkyl; and G is selected from the group consisting of heteroaryl and heterocyclyl that are not thiazolyl or imidazolyl; wherein the heteroaryl and heterocyclyl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, amino, acyl, cycloalkyl, heterocyclyl, aryl, heteroaryl and
wherein the alkyl, alkenyl, alkynyl, alkoxy, acyl, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, alkyl haloalkyl, alkenyl, alkynyl, aryl, hydroxyl, alkoxy, haloalkoxy, —N(Ry)(Rz), cycloalkyl, heterocyclyl, ester and cyano groups; or
R5 and G are taken together with the nitrogen atom to which they are attached to form a heterocyclyl or heteroaryl group, wherein the heterocyclyl and heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, alkoxy, hydroxyl, amino, cycloalkyl, heterocyclyl, aryl and heteroaryl, wherein the alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, heterocyclyl, aryl and heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, alkyl, haloalkyl, alkenyl, alkynyl, aryl, hydroxyl, alkoxy, haloalkoxy, cycloalkyl, ester, and cyano;
Ar is an aryl group optionally substituted with one or more R0;
Het is a heterocyclyl group optionally substituted with one or more R0;
Ru is selected from the group consisting of a bond, alkylene, alkenylene and alkynylene;
Rx is selected from the group consisting of hydrogen, alkyl, cycloalkyl, hydroxyalkyl, haloalkyl, alkenyl and alkynyl; or
—RuORx together form an oxygen-containing 3-7 membered heterocyclic ring, which is optionally substituted with one or more groups selected from the group consisting of halogen, haloalkyl, alkyl, aryl, alkenyl, and alkynyl;
Ry and Rz are each independently selected from the group consisting of hydrogen, alkyl, alkoxy, aryl, alkenyl, alkynyl, cycloalkyl, haloalkoxy and haloalkyl; or
Ry and Rz are taken together with the nitrogen atom to which they are attached to form heterocyclyl or heteroaryl, wherein the heterocyclyl and heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, haloalkyl, alkyl, aryl, acyl, alkenyl and alkynyl, wherein the alkyl is optionally substituted with one or more groups selected from the group consisting of alkoxy and cycloalkyl group;
Q is selected from the group consisting of hydrogen, hydroxyl, alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, cyano, nitro, aryl, heterocyclyl and heteroaryl; wherein the alkyl, alkoxy, cycloalkyl, alkenyl, alkynyl, aryl, heterocyclyl and heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of hydroxyl, halogen and alkyl;
n is 0, 1, or 2.

### Claim 2 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein W1 and W2 are each independently selected from the group consisting of N and CR3, and R3 is selected from the group consisting of hydrogen, alkyl and halogen.

### Claim 3 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein A is selected from the group consisting of NH and O.

### Claim 4 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein R2 is selected from the group consisting of Q group and the following structure:
Q is selected from the group consisting of hydrogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, C3-C7 cycloalkyl, C5-C7 aryl, 5 to 7 membered heterocyclyl and 5 to 7 membered heteroaryl;
R0 is as defined in claim 1.

### Claim 5 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein R3 and R8 are each independently selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, haloalkoxy and —N(Ry)(Rz)
Ry and Rz are as defined in claim 1.

### Claim 6 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein R4 is selected from the group consisting of hydrogen, alkyl and alkoxy.

### Claim 7 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein R6 is selected from the group consisting of hydrogen, halogen, alkyl and alkoxy.

### Claim 8 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein R7 is selected from the group consisting of hydrogen and cyano.

### Claim 9 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein:
R1 is OR10,
R10 is selected from the group consisting of hydrogen, C1-C6 alkyl, —RuORx and —RuN(Ry)(Rz),
Ru is C1-C6 alkylene,
Rx is selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 hydroxyalkyl and C1-C6 haloalkyl,
Ry and Rz are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy and C3-C7 cycloalkyl; or
Ry and Rz are taken together with the nitrogen atom to which they are attached to form 5 to 7 membered heterocyclyl or heteroaryl group; wherein the 5 to 7 membered heterocyclyl and heteroaryl are each optionally substituted with one or more groups selected from the group consisting of halogen, acyl, C1-C6 alkyl, C1-C6 haloalkyl and C6-C10 aryl, wherein the C1-C6 alkyl is optionally substituted with one or more groups selected from the group consisting of C1-C6 alkoxyl and C3-C7 cycloalkyl.

### Claim 10 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein:
R5 is selected from the group consisting of hydrogen and alkyl; and G is selected from the group consisting of 5 to 7 membered heteroaryl group and 5 to 7 membered heterocyclyl group that are not thiazolyl and imidazolyl,
the 5 to 7 membered heteroaryl group and 5 to 7 membered heterocyclyl group are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, acyl, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl groups, wherein the acyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C2-C6 alkenyl, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, —N(Ry)(Rz), C1-C6 haloalkoxy, 5 to 7 membered heterocyclyl, esters and cyano; or,
R5 and G are taken together with the nitrogen atom to which they are attached to form 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl groups, wherein the 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl are each independently or optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl;
Ry and Rz are each independently selected from the group consisting of hydrogen, C1-C6 alkyl, and C1-C6 haloalkyl group; or
Ry and Rz are taken together with the nitrogen atom to which they are attached to form 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl groups, wherein the 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 haloalkyl and C1-C6 alkyl.

### Claim 11 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein:
R5 is selected from the group consisting of hydrogen and alkyl; and G is selected from the group consisting of the following pyrazolyl and isoxazolyl:
wherein the pyrazolyl and isoxazolyl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, acyl, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl; wherein the acyl, C1-C6 alkyl, C1-C6 alkoxy, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C2-C6 alkenyl, hydroxyl, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, —N(Ry)(Rz), C1-C6 haloalkoxy, 5-7 membered heterocyclyl, ester and cyano; or
R5 and G are taken together with the nitrogen atom to which they are attached to form 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl, wherein the 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl are each independently and optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, C1-C6 haloalkoxy, hydroxyl, amino, C3-C7 cycloalkyl, 5 to 7 membered heterocyclyl, C5-C7 aryl and 5 to 7 membered heteroaryl;
Ry and Rz are each independently selected from the group consisting of hydrogen, C1-C6 alkyl and C1-C6 haloalkyl; or
Ry and Rz are taken together with the nitrogen atom to which they are attached to form 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl; wherein the 5 to 7 membered heterocyclyl or 5 to 7 membered heteroaryl are each independently or optionally substituted with one or more groups selected from the group consisting of halogen, C1-C6 haloalkyl and C1-C6 alkyl.

### Claim 12 (depends on 1)

The compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein the compound is selected from the group consisting of:

### Claim 13 (depends on 1)

A deuterated compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, wherein one or more H atoms in the compound of general formula (I) is independently replaced by D atom.

### Claim 14 (depends on 13)

The deuterated compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 13, wherein the compound is selected from the group consisting of:

### Claim 15 (depends on 1)

A method for preparing the compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, comprising the following steps:
the compound of formula (II) is reacted with the compound of formula (III) in the presence of a base in a suitable solvent to give the compound of general formula (I);
the solvent is selected from the group consisting of THF, acetonitrile, dichloromethane and toluene,
the base is selected from the group consisting of triethylamine, N,N-diisopropyl ethyl amine, DMAP and pyridine;
R1, R2, R3, R4, R5, R6, R7, R8, R9, A, W1, W2 and G are as defined in claim 1.

### Claim 16 (depends on 1)

A method for preparing the compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, comprising the following steps:
the compound of formula (IV) is reacted with the compound of formula (V) in the presence of a base in a suitable solvent to give the compound of general formula (I);
the solvent is selected from the group consisting of THF, acetonitrile, dichloromethane, and toluene;
the base is selected from the group consisting of triethylamine, N,N-diisopropylethyl amine, DMAP, and pyridine;
R1, R2, R3, R4, R5, R6, R7, R8, R9, A, W1, W2 and G are as defined in claim 1.

### Claim 17 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, or a deuterated compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof as well as one or more pharmaceutically acceptable carriers.

### Claim 18 (depends on 1)

A method of inhibiting a protein kinase selected from the group consisting of ABL1, AXL, EGFR, FGFR1-4, FLT3, KIT, MERTK, PDGFRα/β, RET, ROS1, NTRK1-3, SRC protein kinase family and PIK3CA, the method comprising administering to a patient in need of it an inhibitory effective amount of a compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1 or a deuterated compound of the compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof or a pharmaceutical composition comprising the compound of general formula (I).

### Claim 19 (depends on 1)

A method of preventing or treating cancer, the method comprising administering to a patient in need of it a therapeutically effective amount of a compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof according to claim 1, or a deuterated compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof, or a pharmaceutical composition comprising the compound of general formula (I) or a pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof, wherein said cancer is lung cancer, gastric cancer, liver cancer, bile duct cancer, breast cancer, nasopharyngeal cancer, pancreatic cancer, ovarian cancer, cervical cancer, endometrial cancer, colorectal cancer, glioma, melanoma, prostate cancer, kidney cancer, esophageal cancer, mesothelioma, head and neck cancer, bladder cancer, salivary gland cancer, anaplastic large cell lymphoma, leukemia, lymphoma, non-Hodgkin's lymphoma or multiple myeloma.

### Claim 20 (depends on 19)

The method according to claim 19, wherein the compound of general formula (I) or pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof or the deuterated compound of general formula (I) or pharmaceutically acceptable salt, solvate, metabolite or prodrug thereof or the pharmaceutical composition is administered in combination with other drugs or cancer therapies for the prevention and/or treatment of cancer.
